Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude/SRI International

This article was originally published in The Gray Sheet

Executive Summary

Collaborating on development of St. Jude's BioXenoGraft, a bioprosthesis "which would have improved durability over conventional tissue valve products" and avoid the need for anticoagulants associated with mechanical valves, St. Jude says. SRI International, a nonprofit corporation chartered by the state of California, will apply its "expertise in implantable bioprosthetic devices" to the development of the product. The work will complement a project between St. Jude and Advanced Tissue Sciences to use ATS' tissue engineering technology to develop tissue heart valves with improved biocompatibility and durability ("The Gray Sheet" Feb. 21, I&W-1)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts